|Daily Range||$133.22 - $134.10|
|52-Week Range||$108.45 - $145.20|
|Dividend (Yield)||$0.00 (1.6%)|
|Average Daily Volume||28,401|
|Current FY EPS||$8.23|
News & Commentary
No, any PR isn't good PR -- especially when you're a corporate figurehead veering into racist, homophobic, or misogynistic territory.
Seattle Genetics (SGEN) successful Hodgkin's lymphoma drug Adcetris has an opportunity for significant growth if ongoing trials succeed.
Impressive Eylea sales growth within and outside the U.S., as well as increased collaborative revenue, pushes Regeneron's profit up 51%.
Pfizer (PFE), Bristol-Myers (BMY), Johnson & Johnson (JNJ) and Bayer (BAYRY) stand to make big money if Portola's anti-coagulant antidote succeeds.
Pfizer (PFE) and Bristol's (BMY) blood thinning drug Eliquis may be gaining ground on Johnson & Johnson (JNJ) and Boehringer.
The FDA recently issued a warning regarding liver damage caused by acetaminophen. Here are four things consumers and investors need to know about the drug, and how it could affect companies like Johnson & Johnson, Novartis, GlaxoSmithKline, and Zogenix.
GlaxoSmithKline receives FDA approval on a novel treatment combination for late-stage melanoma.
Regeneron has had a great run over the past 12 months. Will these 3 bullish indicators -- which also affect Bayer, Novartis, Roche, and Sanofi -- catapult the stock to new heights in 2014?
The market for prostate cancer treatment is $12 billion and growing, but it's getting crowded. That makes this year important as Bayer's Xofigo faces off against Johnson's Zytiga and Medivation's Xtandit.